440 related articles for article (PubMed ID: 16475152)
21. [Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM; Jaillon-Abraham C; Lucas V; Chrétien Y; Mayeur D; Di Palma M; Boaziz C; Grise P; Varette C; Pavlovitch JM; Larregain D; Ecstein E; Untereiner M; Andrieu JM
Bull Cancer; 1997 Apr; 84(4):351-6. PubMed ID: 9238157
[TBL] [Abstract][Full Text] [Related]
22. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma.
Bennouna J; Bompas E; Neidhardt EM; Rolland F; Philip I; Galéa C; Salot S; Saiagh S; Audrain M; Rimbert M; Lafaye-de Micheaux S; Tiollier J; Négrier S
Cancer Immunol Immunother; 2008 Nov; 57(11):1599-609. PubMed ID: 18301889
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
[TBL] [Abstract][Full Text] [Related]
24. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
25. Randomized study of intravenous versus subcutaneous interleukin-2, and IFNalpha in patients with good prognosis metastatic renal cancer.
Négrier S; Perol D; Ravaud A; Bay JO; Oudard S; Chabaud S; Fargeot P; Delva R; Deplanque G; Gravis G; Escudier B;
Clin Cancer Res; 2008 Sep; 14(18):5907-12. PubMed ID: 18794104
[TBL] [Abstract][Full Text] [Related]
26. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial.
Schmidinger M; Steger G; Wenzel C; Locker GJ; Budinsky AC; Brodowicz T; Kramer G; Marberger M; Zielinski CC;
J Immunother; 2001; 24(3):257-62. PubMed ID: 11394504
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.
Canobbio L; Curotto A; Cannata D; Miglietta L; Lavarello A; Giglio C; Franchini R; Cussotto M; Boccardo F
Anticancer Res; 1996; 16(1):541-4. PubMed ID: 8615668
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Krzyzanowska MK; Tannock IF; Lockwood G; Knox J; Moore M; Bjarnason GA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):135-41. PubMed ID: 17009033
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
30. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ; Jac J; Giessinger S; Saxena S; Willis JP
Cancer; 2009 Jun; 115(11):2438-46. PubMed ID: 19306412
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
32. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
34. Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma.
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Ohlmann CH; Varga Z; von Knobloch R; Hofmann R
Anticancer Drugs; 2005 Jun; 16(5):581-5. PubMed ID: 15846124
[TBL] [Abstract][Full Text] [Related]
35. Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer.
Recchia F; De Filippis S; Rosselli M; Saggio G; Cesta A; Fumagalli L; Rea S
Clin Cancer Res; 2001 May; 7(5):1251-7. PubMed ID: 11350891
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
37. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide therapy for metastatic renal cell carcinoma.
Amato RJ; Hernandez-McClain J; Saxena S; Khan M
Am J Clin Oncol; 2008 Jun; 31(3):244-9. PubMed ID: 18525302
[TBL] [Abstract][Full Text] [Related]
39. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
Harshman LC; Li M; Srinivas S
Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
